A Phase 1 Study of ZN-c3 as a Single Agent in Subjects With Solid Tumors
Latest Information Update: 04 Feb 2025
At a glance
- Drugs Azenosertib (Primary) ; Pembrolizumab; Talazoparib
- Indications Carcinoma; Solid tumours; Uterine cancer
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- Sponsors K-Group Beta; Zentalis Pharmaceuticals
Most Recent Events
- 29 Jan 2025 Results published in the Zentalis Pharmaceuticals media release.
- 16 Sep 2024 According to Zentalis Pharmaceuticals media release, company announced that the U.S. Food and Drug Administration (FDA) has lifted the partial clinical hold on studies of azenosertib.The FDA has cleared the Company to resume enrollment in all ongoing azenosertib clinical studies with no changes in the clinical development plan.
- 18 Jun 2024 According to Zentalis Pharmaceuticals media release, The company remains on track to present results from the ZN-c3-001 and Phase 1/2 ZN-c3-006 (MAMMOTH) studies later this year.